A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial

Chest

Volumn 151, Issue 6, 2017, Pages 1239-1246

  Kollef, Marin H ^a   Ricard, Jean Damien ^b,c   Roux, Damien ^b,c   Francois, Bruno ^d   Ischaki, Eleni ^e   Rozgonyi, Zsolt ^f   Boulain, Thierry ^g   Ivanyi, Zsolt ^h   János, Gál ^h   Garot, Denis ⁱ   Koura, Firas ^j   Zakynthinos, Epaminondas ^k   Dimopoulos, George ^l   Torres, Antonio ^m   Danker, Wayne ⁿ   Montgomery, A Bruce ^o  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e KAT HOSPITAL   (Greece)

^f Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^g CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ CHU BRETONNEAU   (France)

^j Kentucky Lung Clinic PSC Appalachian Regional Healthcare   (United States)

^k General Hospital of Larisa   (Greece)

^l UNIVERSITY OF ATHENS   (Greece)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ PAREXEL INTERNATIONAL   (United States)

^o Cardeas Pharma   (United States)

more..

Author keywords

aerosols; antibiotics; pneumonia

Indexed keywords

AMIKACIN PLUS FOSFOMYCIN; ANTIBIOTIC AGENT; COLISTIN; PLACEBO; UNCLASSIFIED DRUG; AMIKACIN; ANTIINFECTIVE AGENT; FOSFOMYCIN;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AEROSOL; ARTICLE; BRONCHOSPASM; CLINICAL PULMONARY INFECTION SCORE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HUMAN; HYPOKALEMIA; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MIC90; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NAUSEA; NEBULIZER; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPTIC SHOCK; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; ADJUVANT CHEMOTHERAPY; AGED; APACHE; CLINICAL TRIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; INHALATIONAL DRUG ADMINISTRATION; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; APACHE; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 85020918525     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.026     Document Type: Article

References (22)

1. Iregui, M., Ward, S., Sherman, G., Fraser, V.J., Kollef, M.H., Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:1 (2002), 262–268.
2. Bekaert, M., Timsit, J.F., Vansteelandt, S., et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 184:10 (2011), 1133–1139.
3. Kollef, M.H., Hamilton, C.W., Ernst, F.R., Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 33:3 (2012), 250–256.
4. Sievert, D.M., Ricks, P., Edwards, J.R., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1 (2013), 1–14.
5. Lodise, T.P., Sorgel, F., Melnick, D., Mason, B., Kinzig, Drusano, G.L., Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 55:4 (2011), 1606–1610.
6. Ehrmann, S., Roche-Campo, F., Sferrazza Papa, G.F., et al. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 39:6 (2013), 1048–1056.
7. Palmer, L.B., Smaldone, G.C., Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 189:10 (2014), 1225–1233.
8. Lu, Q., Yang, J., Liu, Z., et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 184:1 (2011), 106–115.
9. Lu, Q., Luo, R., Bodin, L., et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117:6 (2012), 1335–1347.
10. Arnold, H.M., Sawyer, A.M., Kollef, M.H., Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 57:8 (2012), 1226–1233.
11. Montgomery, A.B., Rhomberg, P.R., Abuan, T., Walters, K.A., Flamm, R.K., Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother 58:7 (2014), 3714–3719.
12. Montgomery, A.B., Rhomberg, P.R., Abuan, T., Walters, K.A., Flamm, R.K., Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother 58:7 (2014), 3708–3713.
13. Montgomery, A.B., Vallance, S., Abuan, T., Tservistas, M., Davies, A., A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® Inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 27:6 (2014), 441–448.
14. Li Bassi G, Aguilera E, Chiurazzi C, et al. The effects of nebulized amikacin/fosfomycin and systemic meropenem on severe amikacin-resistant meropenem-susceptible Pseudomonas aeruginosa pneumonia. Abstract presented at: European Congress of Clinical Microbiology and Infectious Diseases Meeting; April 9-12, 2016; Amsterdam, The Netherlands.
15. Singh, N., Rogers, P., Atwood, C.T., Wagener, M.M., Yu, V.L., Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:2 Pt 1 (2000), 505–511.
16. Pocock, S.J., Ariti, C.A., Collier, T.J., Wang, D., The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 33:2 (2012), 176–182.
17. Miller, D.D., Amin, M.M., Palmer, L.B., Shah, A.R., Smaldone, G.C., Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 168:10 (2003), 1205–1209.
18. Huang, J.X., Blaskovich, M., Pelingon, R., et al. Mucin binding reduces colistin antimicrobial activity. Antimicrob Agents Chemother 59:10 (2015), 5925–5931.
19. Eschenbacher, W.L., Boushey, H.A., Sheppard, D., Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 129:2 (1984), 211–215.
20. Hahn, M., Tservistas, M., Hetzer, U., et al. In vitro assessment of a novel nebulizer for mechanically ventilated patients based on the eFlow® technology. [abstract] J Aerosol Med Pulm Drug Deliv 22:2 (2009), 187–188.
21. O'Riordan, T.G., Palmer, L.B., Smaldone, G.C., Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am Respir Crit Care Med 149:1 (1994), 214–219.
22. Fihman, V., Messika, J., Hajage, D., et al. Five-year trends for ventilator-associated pneumonia: correlation between microbiological findings and antimicrobial drug consumption. Int J Antimicrob Agents 46:5 (2015), 518–525.